Dr. Allen Barnett Receives Distinguished Alumni Award from the University at Buffalo Friday, March 28th, 2014

Kinex is pleased to congratulate Dr. Allen Barnett, Kinex Founder and President Emeritus on receiving a Distinguished Alumni Award from the University at Buffalo. Read more>

Kinex and Zenith Technology to Initiate Clinical Studies of an Oral Form of Paclitaxel (Oraxol) in New Zealand Wednesday, March 19th, 2014

Kinex Pharmaceuticals announced today to having received regulatory and ethics approvals to initiate the first clinical study of an oral form of paclitaxel (Oraxol) in Dunedin Hospital in Otago, New Zealand.  This is the first clinical study of Oraxol in New Zealand. Oraxol is also currently in clinical studies conducted in Korea and in the United States of America. Read more>

Kinex Completes Oversubscribed USD $40 Million Private Placement Equity Raise Tuesday, March 4th, 2014

Kinex Pharmaceuticals announced today the successful completion of an oversubscribed USD $40 million private placement of equity which was completed on February 28, 2014. Proceeds from this round, coupled with cash on hand, will be used to fund the completion of the commercialization of its oral form of paclitaxel (Oraxol) and irinotecan (Oratecan) in select markets outside of the United States. In addition, the proceeds will fund mid-stage clinical trials in the United States of four of eight Kinex drug candidates. Read more>

Kinex Pharmaceuticals’ Vice-Chairman Named One of WNY’s Most Influential People in 2014 Friday, February 7th, 2014

Kinex Pharmaceuticals’ Vice-Chairman, Charles E. Lannon, has been named by Business First Buffalo, one of WNY’s most influential people in their Power 250 list for 2014. Mr. Lannon has been Vice-Chairman of Kinex since March 2010 and is also President of Strategic Advisory, Inc., a consulting firm specializing in the fields of health care, real estate, and start-up ventures. Read more>

Kinex and PharmaEssentia Expand Drug Development Partnership Thursday, February 6th, 2014

Kinex Pharmaceuticals and PharmaEssentia Corporation (Taiwan) announced today the execution of a new licensing agreement granting PharmaEssentia exclusive development and commercial rights to Oraxol and Oratecan in Taiwan and Singapore.  Kinex will receive an upfront payment, milestones, and royalties.  PharmaEssentia has also committed to conducting clinical studies in Taiwan to contribute to the global registration programs for Oraxol and Oratecan. The companies currently have a licensing agreement in place in certain Asian territories for the dermatology preparations of Kinex’s dual Src/Pretubulin Inhibitor, KX01. Read more>